Riad Salem1, Siddharth A Padia2, Marnix Lam3, Carlo Chiesa4, Paul Haste5, Bruno Sangro6, Beau Toskich7, Kirk Fowers8, Joseph M Herman9, S Cheenu Kappadath10, Thomas Leung11, Daniel Y Sze12, Edward Kim13, Etienne Garin14. 1. Department of Radiology, Northwestern Feinberg School of Medicine, 676 N. St. Clair, Suite 800, Chicago, IL, USA. rsalem1@nm.org. 2. Department of Radiology, University of California-Los Angeles, Los Angeles, CA, USA. 3. Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands. 4. Department of Nuclear Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. 5. Department of Interventional Radiology, Indiana University School of Medicine, Indianapolis, IN, USA. 6. Liver Unit, Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain. 7. Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA. 8. Boston Scientific Corporation, Marlborough, MA, USA. 9. Department of Radiation Medicine, Northwell Health, New Hyde Park, NY, USA. 10. Department of Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 11. Comprehensive Oncology Centre, Hong Kong Sanatorium and Hospital, Hong Kong, Hong Kong. 12. Department of Radiology, Stanford University School of Medicine, Palo Alto, CA, USA. 13. Department of Interventional Radiology, Mount Sinai, New York City, NY, USA. 14. INSERM, INRA, Centre de Lutte Contre Le Cancer Eugène Marquis, Institut NUMECAN (Nutrition Metabolisms and Cancer), Univ Rennes, 35000, Rennes, France.
Abstract
PURPOSE: In light of recently published clinical reports and trials, the TheraSphere Global Dosimetry Steering Committee (DSC) reconvened to review new data and to update previously published clinical and dosimetric recommendations for the treatment of hepatocellular carcinoma (HCC). METHODS: The TheraSphere Global DSC is comprised of health care providers across multiple disciplines involved in the treatment of HCC with yttrium-90 (Y-90) glass microsphere-based transarterial radioembolization (TARE). Literature published between January 2019 and September 2021 was reviewed, discussed, and adjudicated by the Delphi method. Recommendations included in this updated document incorporate both the results of the literature review and the expert opinion and experience of members of the committee. RESULTS: Committee discussion and consensus led to the expansion of recommendations to apply to five common clinical scenarios in patients with HCC to support more individualized efficacious treatment with Y-90 glass microspheres. Existing clinical scenarios were updated to reflect recent developments in dosimetry approaches and broader treatment paradigms evolving for patients presenting with HCC. CONCLUSION: Updated consensus recommendations are provided to guide clinical and dosimetric approaches for the use of Y-90 glass microsphere TARE in HCC, accounting for disease presentation, tumor biology, and treatment intent.
PURPOSE: In light of recently published clinical reports and trials, the TheraSphere Global Dosimetry Steering Committee (DSC) reconvened to review new data and to update previously published clinical and dosimetric recommendations for the treatment of hepatocellular carcinoma (HCC). METHODS: The TheraSphere Global DSC is comprised of health care providers across multiple disciplines involved in the treatment of HCC with yttrium-90 (Y-90) glass microsphere-based transarterial radioembolization (TARE). Literature published between January 2019 and September 2021 was reviewed, discussed, and adjudicated by the Delphi method. Recommendations included in this updated document incorporate both the results of the literature review and the expert opinion and experience of members of the committee. RESULTS: Committee discussion and consensus led to the expansion of recommendations to apply to five common clinical scenarios in patients with HCC to support more individualized efficacious treatment with Y-90 glass microspheres. Existing clinical scenarios were updated to reflect recent developments in dosimetry approaches and broader treatment paradigms evolving for patients presenting with HCC. CONCLUSION: Updated consensus recommendations are provided to guide clinical and dosimetric approaches for the use of Y-90 glass microsphere TARE in HCC, accounting for disease presentation, tumor biology, and treatment intent.
Authors: William A Dezarn; Jeffery T Cessna; Larry A DeWerd; Wenzheng Feng; Vanessa L Gates; James Halama; Andrew S Kennedy; Subir Nag; Mehrdad Sarfaraz; Varun Sehgal; Reed Selwyn; Michael G Stabin; Bruce R Thomadsen; Lawrence E Williams; Riad Salem Journal: Med Phys Date: 2011-08 Impact factor: 4.071
Authors: Siddharth A Padia; Guy E Johnson; Kathryn J Horton; Christopher R Ingraham; Matthew J Kogut; Sharon Kwan; Sandeep Vaidya; Wayne L Monsky; James O Park; Renuka Bhattacharya; Daniel S Hippe; William P Harris Journal: J Vasc Interv Radiol Date: 2017-03-30 Impact factor: 3.464
Authors: Ahmed Gabr; Ahsun Riaz; Guy E Johnson; Edward Kim; Siddharth Padia; Robert J Lewandowski; Riad Salem Journal: Eur J Nucl Med Mol Imaging Date: 2020-08-04 Impact factor: 9.236
Authors: John D Louie; Nishita Kothary; William T Kuo; Gloria L Hwang; Lawrence V Hofmann; Michael L Goris; Andrei H Iagaru; Daniel Y Sze Journal: J Vasc Interv Radiol Date: 2009-04-05 Impact factor: 3.464
Authors: Riad Salem; Kenneth G Thurston; Brian I Carr; James E Goin; Jean-Francois H Geschwind Journal: J Vasc Interv Radiol Date: 2002-09 Impact factor: 3.464
Authors: Ahmed Gabr; Srirajkumar Ranganathan; Samdeep K Mouli; Ahsun Riaz; Vanessa L Gates; Laura Kulik; Daniel Ganger; Haripriya Maddur; Christopher Moore; Elias Hohlastos; Nitin Katariya; Juan Carlos Caicedo; Aparna Kalyan; Robert J Lewandowski; Riad Salem Journal: J Hepatol Date: 2020-03-05 Impact factor: 25.083
Authors: Cynthia De la Garza-Ramos; Cameron J Overfield; S Ali Montazeri; Harris Liou; Ricardo Paz-Fumagalli; Gregory T Frey; J Mark McKinney; Charles A Ritchie; Zlatko Devcic; Andrew R Lewis; Denise M Harnois; Tushar Patel; Beau B Toskich Journal: J Hepatocell Carcinoma Date: 2021-07-30